Results 91 to 100 of about 9,895 (222)
Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi +5 more
wiley +1 more source
A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix +4 more
wiley +1 more source
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon +11 more
wiley +1 more source
AI‐Enabled Precision Dosing in Pediatrics: Enhancing Model‐Informed Decision Making
Ensuring safe and effective pharmacotherapy for children remains a central challenge in clinical pharmacology, yet rapid advances in AI have not translated into clinical practice. This Perspective highlights how AI‐enabled approaches can enhance model‐informed decision making for precision dosing.
Kei Irie, Tomoyuki Mizuno
wiley +1 more source
Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy [PDF]
The Physiologically-based Pharmacokinetic (PBPK) approach was successfully used within four projects to meet challenges in drug development and pharmacotherapy.
Moj, Daniel Andreas
core +1 more source
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara +20 more
wiley +1 more source
Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang +2 more
wiley +1 more source
ZeroPM piece 12 PBPK modelling
ZeroPM piece 12 about PBPK modelling. The presentation can be viewed as a film on the ZeroPM youtube channel.
openaire +2 more sources
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source

